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Background: There are 481 ultra-conserved regions (UCRs) longer than 200 bases in the genomes of human,
mouse and rat. These DNA sequences are absolutely conserved and show 100% identity with no insertions or
deletions. About half of these UCRs are reported as transcribed and many correspond to long non-coding RNAs
(lncRNAs).
Methods: We used custom microarrays with 962 probes representing sense and antisense sequences for the 481
UCRs to examine their expression across 374 normal samples from 46 different tissues and 510 samples
representing 10 different types of cancer. The expression in embryonic stem cells of selected UCRs was validated by
real time PCR.
Results: We identified tissue selective UCRs and studied UCRs in embryonic and induced pluripotent stem cells.
Among the normal tissues, the uc.283 lncRNA was highly specific for pluripotent stem cells. Intriguingly, the uc.283-plus
lncRNA was highly expressed in some solid cancers, particularly in one of the most untreatable types, glioma.
Conclusion: Our results suggest that uc.283-plus lncRNA might have a role in pluripotency of stem cells and in the
biology of glioma.Background
Long non-coding RNAs (lncRNAs) are involved in many
biological processes [1]. Transcribed ultra-conserved re-
gions (T-UCRs) are a large portion of the so-called ultra-
conserved regions (UCRs). The 'ultra-conserved' term
was originally proposed for genomic regions longer than
200 bp that are absolutely conserved (100% homology
with no insertions or deletions) in human, mouse, and
rat genomes [2]. Many of these elements possess tissue-
specific enhancer activity [3-5] and others have been
shown to associate with splicing regulators. Evolution-
ary conservation has become a powerful tool to identify* Correspondence: s.volinia@unife.it
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A high proportion of UCRs show extreme conservation
within mammals only and nearly 47% of UCRs in human
have been localized to exons of genes involved in RNA
processing or in the regulation of transcription and devel-
opment [2,7]. The reasons for this extreme conservation
remain a mystery, but it was proposed that UCRs play a
role in the ontogeny and phylogeny of mammals and
other vertebrates. This idea is supported by the identifica-
tion of a distal enhancer and an ultra-conserved exon de-
rived from a retroposon active more than 400 million
years ago in lobe-finned fishes and terrestrial verte-
brates, and maintained as active in the 'living fossil'
coelacanth [2]. Another study showed the concurrent
presence of enhancer and transcript functions in non-
exonic UCRs, and suggested that they may belong to
non-coding RNAs (ncRNAs) [8]. Recently, a positive cor-
relation of expression with conservation and epigeneticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[9]. Despite still having largely unknown roles, T-UCRs
are thus now thought to act as 'regulators' of other RNAs
[10].
Recent studies suggested that UCRs could contribute
to the development of malignancies [11,12]. Genome-
wide profiling revealed that UCRs have distinct signa-
tures in human leukemias and carcinomas [13] and are
frequently located at fragile sites and in cancer-associated
genomic regions [14]. Clinical findings also suggested that
UCR signatures can have independent prognostic value in
high-risk neuroblastoma patients [15] by providing add-
itional prognostic value in conjunction with N-MYC activ-
ity/amplification [16]. Additionally, SNPs within UCRs
were associated with increased familial breast cancer risk
[17].
We performed this large scale study to identify UCR
activity in cancer, analyzing almost 900 human samples
from a panel of 46 normal tissues and 10 solid cancers
using a custom-made microarray platform.
Methods
UCR expression arrays
We studied the expression of UCRs using the Ohio State
University Comprehensive Cancer Center (OSUCCC)
custom microarray [18]. The Gene Expression Omnibus
describes the OSU-CCC 4.0 platform under accession
number GPL14184. Briefly, a sense and an anti-sense
40-mer probe were designed for each of 481 UCRs. Each
probe was printed in duplicate in two different slide lo-
cations, and therefore quadruplicate measures were
available. Total RNA (2 μg) were used for labeling and
hybridization. The microarrays were hybridized in 6X
SSPE (0.9 M NaCl/60 mM NaH2PO4 · H2O/8 mM EDTA,
pH 7.4)/30% formamide at 25°C for 18 h, washed in 0.75X
TNT (Tris HCl/NaCl/Tween 20) at 37°C for 40 minutes.
Processed slides were scanned using a microarray scanner
(Axon Molecular Devices, Sunnyvale, CA, USA), with the
laser set to 635 nm, at a fixed PMT (photomultiplier tube)
setting, and a scan resolution of 10 mm. Microarray
images were analyzed using GenePix Pro and post-
processing was performed essentially as described earlier
[18].
Data analysis
T-UCRs were retained when present in at least 20% of
samples and when at least 20% of them had a fold
change of more than 1.5 from the gene median. Absent
calls were thresholded prior to normalization and statis-
tical analysis. Normalization was performed by using
quantiles [19]. First, all samples were classified according
to organ, tissue and cell type; the samples were then
grouped in systems (Additional file 1) and cancer types
(Additional file 2). To assess the specificity of UCRexpression across groups we used information content
(IC) [20]. Differentially expressed RNAs were identified
using t-tests over two-class experiments or F-tests over
multiple classes (that is, various normal tissues) within
the class comparison tool [21].
Computational methods and folding free energies
Computational methods were used to investigate uc.283-
plus and predict secondary structure for its RNA se-
quence. To investigate secondary structure, we used the
RNAfold web server in the freely available ViennaRNA
package version 2.0 to compute the centroid secondary
structure and the corresponding free energy changes for
folding, the minimum free energy (MFE; kcal/mol). In
order to detect putative microRNA (miRNA) target sites
in the considered region, we used IntaRNA, freely avail-
able online [22,23]. Calculation of accessibility is based
on ensemble free energies. Ensemble free energies were
calculated using a partition function approach assuming
global folding of the ncRNA and local folding of the
mRNA. For this purpose, RNAfold and RNAup are inte-
grated into IntaRNA via the ViennaRNA library [24].
Highly stable miRNA-target duplexes are represented as
having a very low hybridization energy.
RNA expression and validation
Mouse embryonic stem cell (ESC) lines (V6.4; hybrid
129/C57Bl/6) were cultured at 37°C in 5% CO2 in spe-
cific medium and total RNA was extracted using TRIzol.
RNA samples were treated with 1 U DNase I Ampl Grade
(Invitrogen Life Technology, Carlsbad, CA, USA) to re-
move any contaminating genomic DNA.
Total RNA was reverse transcribed using random hex-
amers (Invitrogen Life Technologies, Carlsbad, CA, USA).
T-UCR expression was quantified by quantitative PCR
(qPCR) with SYBR green. All reactions were performed in
triplicate and 18S rRNA was used as reference. The tri-
plicate Ct values were averaged and normalized Ct (ΔCt)
calculated. The living conditions of the mice were ap-
propriate for their species and all mouse experiments
were approved by the Institutional Animal Care and
Use Committee (IACUC) and University Laboratory
Animal Resources (ULAR) of The Ohio State University.
The animals were euthanized as per the IACUC approved
guidelines and protocols before harvesting the tissues.
RNA purity was assessed by the ratio of absorbance at 260
and 280 nm (A260/280 nm) using a NanoDrop ND-1000
(NanoDrop Inc., Wilmington, DE, USA). All tissues were
obtained under the guidelines of approved protocols from
the Ohio State University Internal Review Board and
informed consent was obtained from each subject. RNA
profiles for the human tissue and cell line samples have
been deposited at ArrayExpress (E-TABM-969 and E-
TABM-970) and at the NCBI Gene Expression Omnibus
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Express (E-TABM-971 for breast carcinoma, E-TABM-
46 for colorectal adenocarcinoma, E-TABM-22 for lung
cancer, E-TABM-343 for ovarian carcinoma, and E-
TABM-49 for prostate adenocarcinoma), and at the Gene
Expression Omnibus (GSE7828 for colorectal carcinoma,
GSE20099 and GSE24839 for esophagus carcinoma,
GSE53504 for glioma and GSE14936 for lung adenocar-
cinoma and squamous carcinoma).
Results and discussion
T-UCR expression in normal human tissues
We tested the expression of UCRs in 374 samples from
46 types of normal tissues, belonging to 16 histological
groups [25]. For UCR profiling we used the OSUMC
microarray platform, previously validated in two large
scale studies [18,26]. This platform has probes for 481
putative T-UCRs in either genomic strand (designated
‘plus’ or ‘minus’; in some other studies defined ‘+’ or
‘+A’, respectively). A global analysis showed that only a
portion of the UCRs (296 out of 962) was expressed inFigure 1 Distinct T-UCR signatures in different clusters of normal tiss
normal tissues grouped by 16 systems. The tissue selectivity was calculated
represents a system. The most represented cluster was the epidermis; 15 Thuman tissues (P-value <0.001; Additional file 3); 48% of
these were non-exonic, 26% putative exonic and 26%
exonic, proportions that reflect previously published
studies [13,14]. Fifty-seven T-UCRs were transcribed bi-
directionally (Additional file 4). Tissue selectivity was
calculated using the IC [20]. The most tissue-selective
UCRs were represented by a group of 15 UCRs, mostly
expressed in epidermis, with an IC value ranging from
3.23 to 1.70 (Figure 1; Additional file 5). These 15 T-
UCRs were not located in the same genomic cluster.
Another tissue-specific RNA was uc.450-plus, which
is highly expressed in the central nervous system. This
finding confirms previous data showing that uc.450 was
expressed in the dorsal root ganglion and the neural tube
[27]. In particular, Visel et al. [27] hypothesized an enhan-
cer function for hs385, which fully includes uc.450. Inter-
estingly, the opposite probe, uc.450-minus, was specific
for the respiratory system. Uc.174-minus, located on the
opposite strand of theMATR3 exon, was expressed mainly
in the respiratory system and epidermis. The placenta
was characterized by the expression of uc.319-minusues (information content standardization). T-UCR selectivity in 46
by using the information content (IC), shown on the y-axis; each color
-UCRs showed strong differential expression (IC >2) for this cluster.
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to the gastrointestinal system. Uc.43-minus (intronic; our
probe is homologous to Mus musculus CN668140 EST),
uc.75-minus, located on the opposite strand of the last
exon of ZEB2, and uc.42-plus (intronic) were expressedFigure 2 Expression levels of uc.283-plus in embryonic stages and ad
different embryonic tissues: ESCs, induced pluripotent stem cells (IPSCs), 7
definitive endoderm and spontaneously differentiating monolayers. (B) Rea
is expressed at higher levels in mouse ESCs (ES) than in adult tissues, such
miR-302 was used as a positive control. Error bars represent standard deviain both liver and the respiratory system. In addition,
uc.417-minus was expressed in adipose tissue and in
the gastrointestinal system. The only UCR selective for
embryo was uc.283-plus, on which we focus for the rest of
this study.ult tissues. (A) Percentage of total uc.283-plus expression in seven
day and 14 day embryoid bodies (EB7 and EB14), trophoblasts,
l-time PCR confirms the results of the microarray analysis. Uc.283-plus
as spleen, seminal vesicles (SV), thymus, lungs and bone marrow (BM).
tion. **P-values <0.01.
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stem cells
Our extensive study of UCR tissue selectivity identified
only one RNA specific for the embryo. To further in-
vestigate this finding we studied ESCs and induced plu-
ripotent stem cells. Uc.283-plus, a 277 nucleotide-long
sequence located at chr10:50,604,757-50,605,033, was
sufficient to discriminate between adult tissues and plu-
ripotent stem cells. Figure 2A shows the expression of
uc.283-plus at distinct stages of differentiation. Uc.283-
plus displayed high values in human ESCs and induced
pluripotent stem cells, increased in trophoblasts at 7 and
14 days of embryoid body differentiation, and decreased
in definitive endoderm to reach the lowest values in
spontaneously differentiated monolayers.
To validate our microarray data that suggest uc.283-
plus is pluripotent specific, we used qPCR on RNAs ex-
tracted from the mouse ESCs and RNAs from five mouse
adult tissues (spleen, seminal vesicles, thymus, lung, and
bone marrow). We used ESC-specific miR-302 as a positive
ncRNA control [20,25]. The qPCR (Figure 2B) confirmed
strong and mouse ESC-selective expression for bothFigure 3 Uc.283-plus expression in solid cancers based on 510 sampl
adenocarcinoma. No expression was detected in breast lobular and ductal
carcinoma. Error bars represent standard deviation.miR-302 and uc.283-plus (Wilcoxon test P-value <0.01)
(Additional file 6). No enhancer activity was associated in
Vista Enhancer Browser [5] with uc.283. In a further quest
to investigate the possible function of uc.283, we analyzed
a 2,000 bp region surrounding this UCR using the UCSC
Genome Browser. In the H1-hESC chromatin state seg-
mentation (HMM track from ENCODE/Broad), this se-
quence might be an inactive or poised promoter [28]. In
addition, the edges of uc.283 overlap with the initial tracts
of two open chromatin regions (OpenChrom_15681 and
OpenChrom_15682). Data from the methyl 450 K bead
array track (ENCODE/HAIB) showed that, in close prox-
imity to the start of uc.283-plus, the CpG sequence was
not methylated in H1-hESC and human umbilical vein
endothelial cells, and partially or totally methylated in
other cell types. These findings, together with the proxim-
ity to open chromatin regions, suggested that uc.283-plus
could be located in a euchromatic region during embry-
onic development and in ESCs. Furthermore, uc.283-plus
is not present in the catalogue of lncRNAs originated from
divergent transcription at promoters of active protein-
coding genes [29]. In particular, there seems to be noes. The highest expression was in glioma, followed by prostate
carcinoma and in ovarian cancers. NSCLC, non-small-cell lung
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land, containing the DRGX (Dorsal root ganglia homeo-
box) promoter (on the opposite strand).Among solid cancers uc.283-plus is mostly expressed in
glioma
Cancer stem cells are a highly debated issue in oncology
[30,31]. Since uc.283 was associated with pluripotency,
we assessed its RNA levels in about 500 tumors from
several types of solid cancers. Surprisingly, uc.283-plus
was over-expressed in prostate adenocarcinoma and gli-
oma samples (Figure 3). Recently, lncRNAs were in-
vestigated in glioma to define grade and histological
differentiation of the tumor [32]. The highest levels of
expression were found in glioma, considered one of the
most aggressive cancers with high propensity for prolif-
eration and tissue invasion. It is tempting to speculate
that the high expression of uc.283-plus in glioma is cor-
related with a 'cancer stem cell phenotype', a well-
studied event occurring in glioma [33]. Interestingly,
Lujambio et al. [34] identified an RNA in the uc.283
genomic region but transcribed from the opposite strand
in various types of cancer cell lines. They also showed that
uc.283-minus undergoes specific CpG island hypermethy-
lation, suggesting that it could be regulated by epigenetic
alteration. Recently, Hudson et al. [35] confirmed the
up-regulation of uc.283-minus in a prostate cancer
cell line treated with the DNA hypomethylating agent
5-azacytidine and with the histone deacetylase inhibi-
tor trichostatin A. Hudson et al. produced a list of all
the possible ucRNA-mRNA interactions based on se-
quence complementarity according to the thermody-
namics of the loop-loop RNA interactions [36,37]. In
order to assess whether uc.283-plus has a functional role,
we checked for possible interactions with the mRNAs
listed but did not find any. Subsequently, we hypothesized
that it has a 'sponge function' for recruitment of miRNAs
or other class of ncRNAs. We examined the possible
secondary structure of uc.283-plus (Figure S1A,B in
Additional file 7) [24] and submitted the RNA sequence
to the web-tool application RegRNA2.0 [38], analyzing
predicted miRNA target sites with a score ≥150 and a free
energy of -20 or less. We found that our transcript se-
quence could be a target of three miRNAs: hsa-miR-455-
5p, has-miR-640 and has-miR-1909-3p. We verified these
possible interactions using another algorithm, IntaRNA
(Figure S1C in Additional file 7) [22]. Interestingly, hsa-
miR-1909-3p was discovered in human ESCs by deep se-
quencing of small RNA libraries [39] and targeted genes,
such as DICER1, SOX2 and NOTCH1 [40]. Hsa-miR-455-
5p and hsa-miR-640 were deregulated in several cancers
but were not the most abundant isoforms and they have
not been well characterized yet [41,42]. Very recently,Liz et al. [10] showed that the long ncRNA uc.283-minus
controlled pri-miRNA processing. This ncRNA-ncRNA
interaction prevents pri-miRNA-195 cleavage by Drosha.
Therefore, understanding the interactions of this kind
of ncRNA is of particular importance to pinpoint their
biological meaning.Conclusion
We report here the genome-wide analysis of UCR tissue
selectivity among 16 human histologic groups, corre-
sponding to 46 different normal tissues. A fraction of
UCRs were tissue-selective, while others were broadly
expressed. Uc.283-plus was highly expressed in pluripo-
tent ESCs and induced pluripotent stem cells. Uc.283-plus
may play an important role in pluripotency and among
solid cancers it is highly expressed in glioma. The under-
standing of the biological roles of UCRs, as those of the
other lncRNAs, remains an open challenge. This study
can be a starting point for the further characterization of
UCR activities in normal and cancer tissues.Additional files
Additional file 1: Table S1. The number of microarray chip samples
used is reported for each system type.
Additional file 2: Table S2. The number of microarray chip samples
used is reported for each cancer type.
Additional file 3: Table S3. Class comparison analysis: expression levels
of tissue-selective T-UCRs.
Additional file 4: Table S4. T-UCR that are bidirectional in normal
cluster tissues.
Additional file 5: Table S5. Tissue specific T-UCRs in normal tissues. Sorted
by information content (IC). The genomic coordinates came from hg19.
Additional file 6: Table S6. Expression levels are calculated as 2(-ΔΔCT)
using 18S rRNA as a reference. Average of at least three experiments,
each PCR performed in triplicate. Standard errors (ERR.ST.) are reported.
Additional file 7: Figure S1. (A) The uc.283-plus folding structure for
the minimum free energy prediction. The optimal secondary structure
has a minimum free energy of -65.70 kcal/mol. (B) The centroid secondary
structure with a minimum free energy of -32.80 kcal/mol. (C) Hsa-miR-640,
hsa-miR-1909-3p and hsa-miR-455-4p target uc.283-plus in three different
positions with different hybridization energy values.
Abbreviations
bp: base pair; ESC: embryonic stem cell; IC: information content;
lncRNA: long non-coding RNA; miRNA: microRNA; ncRNA: non-coding RNA;
qPCR: quantitative polymerase chain reaction; SNP: single-nucleotide
polymorphism; T-UCR: transcribed ultra-conserved region; UCR: ultra-
conserved region.
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